Drugs Approved for Anal Cancer

Key Takeaways

• The FDA has approved specific chemotherapy and immunotherapy agents for anal cancer, primarily targeting squamous cell carcinoma.
• The standard first-line regimen combines 5-fluorouracil and mitomycin C with concurrent radiation therapy.
• Nivolumab and pembrolizumab are FDA-approved immunotherapy options for patients with advanced or metastatic anal cancer.
• Treatment selection depends on disease stage, patient health status, and prior therapy history.
• Close coordination with a multidisciplinary oncology team is essential for optimizing outcomes and managing side effects.

FDA-Approved Drugs for Anal Cancer Treatment

FDA-approved medications for anal cancer represent the cornerstone of evidence-based care for this disease. The U.S. Food and Drug Administration (FDA) evaluates drugs through rigorous clinical trials before granting approval, ensuring that any authorized treatment has demonstrated measurable benefit in safety and efficacy. For anal cancer, approvals span both chemotherapy and immunotherapy classes, reflecting advances in understanding the disease’s biology.

The majority of anal cancers—roughly 85 to 90 percent—are squamous cell carcinomas (SCC), according to the National Cancer Institute. This histological predominance shapes which drugs receive regulatory attention. For localized disease, the FDA-endorsed standard of care has long been a combination of chemotherapy with concurrent radiation, known as chemoradiation. For metastatic or recurrent cases, additional systemic agents have received approval based on compelling trial data.

The following table summarizes the key FDA-approved agents used in anal cancer management, their drug class, and their primary clinical indication:

Chemotherapy and Immunotherapy Options for Squamous Cell Anal Cancer

The anal cancer chemotherapy drugs list begins with 5-fluorouracil (5-FU) and mitomycin C, which together form the backbone of first-line treatment for localized squamous cell anal cancer. This combination, used alongside radiation therapy, was established through landmark trials in the 1970s and 1980s and remains the globally recognized standard today. The regimen works by sensitizing cancer cells to radiation while simultaneously targeting tumor DNA replication.

Capecitabine, an oral prodrug that converts to 5-FU in the body, is used as an alternative when intravenous administration is not feasible, offering comparable efficacy with greater patient convenience. Cisplatin, a platinum compound, may replace mitomycin C in certain protocols, particularly for patients with specific contraindications or in the metastatic setting. Clinical guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) continue to refine which combinations are preferred based on evolving trial evidence.

Approved immunotherapy drugs for anal cancer have transformed the treatment landscape for patients with advanced or relapsed disease. Nivolumab and pembrolizumab are both programmed death-1 (PD-1) checkpoint inhibitors that restore the immune system’s ability to recognize and attack cancer cells. The FDA granted approval for nivolumab based on the phase 2 NCI9673 trial, which demonstrated meaningful response rates in patients with previously treated metastatic SCC of the anal canal. Pembrolizumab received accelerated approval through the KEYNOTE-158 basket trial, which showed durable responses across multiple solid tumors with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) characteristics, including anal cancer.

First-Line Drugs for Squamous Cell Anal Cancer

The first-line drugs for squamous cell anal cancer in the localized setting are 5-FU and mitomycin C delivered concurrently with external beam radiation therapy. This chemoradiation approach achieves local disease control in approximately 80 to 90 percent of patients with early-stage tumors, according to data published in the Journal of Clinical Oncology. The goal is organ preservation—avoiding the need for surgical resection of the anal sphincter—while eradicating the primary tumor.

For patients presenting with metastatic disease at diagnosis, no single universally approved first-line systemic regimen currently exists; however, carboplatin plus paclitaxel has emerged as a widely adopted option based on the InterAACT trial, which compared it favorably to cisplatin plus 5-FU in terms of tolerability and overall survival. Oncologists select regimens based on performance status, comorbidities, and institutional experience, always within the context of applicable guidelines.

Immunotherapy Biomarker Considerations

Patient selection for checkpoint inhibitor therapy often involves biomarker testing. Tumors are evaluated for PD-L1 expression, MSI-H status, and tumor mutational burden (TMB), as these characteristics may predict a stronger response to immunotherapy. Pembrolizumab’s accelerated FDA approval in MSI-H/dMMR solid tumors—the first tissue-agnostic oncology approval in FDA history—applies to anal cancers harboring these molecular features. Genetic testing at diagnosis or recurrence is therefore an integral part of modern anal cancer workup.

How Drugs Approved for Anal Cancer Are Used in Clinical Practice

Anal cancer treatment options and approved drugs are deployed according to disease stage and patient-specific factors. In early-stage anal cancer (stages I and II), chemoradiation with 5-FU and mitomycin C is the definitive treatment approach. Patients receive continuous or bolus 5-FU infusion during the first and last weeks of radiation, with mitomycin C administered as a single intravenous dose at the start of therapy. This schedule minimizes cumulative toxicity while maximizing radiosensitization.

For locally advanced disease (stage III), the same chemoradiation backbone is used, though treatment fields may be extended to include pelvic and inguinal lymph nodes. Some protocols incorporate an additional radiation boost to the primary tumor. Response assessment typically occurs eight to twelve weeks after completing chemoradiation, using clinical examination and imaging, before determining whether further intervention is necessary.

In the metastatic or recurrent setting, systemic chemotherapy or immunotherapy is initiated as the primary treatment modality. Oncologists sequence these agents based on prior exposure, toxicity profiles, and patient goals of care. Immunotherapy with nivolumab or pembrolizumab is generally reserved for patients who have progressed on at least one line of platinum-based chemotherapy, though evolving data may shift this practice. Supportive care, including antiemetics, growth factors, and pain management, is integrated throughout all treatment phases to maintain quality of life.

What to Expect When Starting Anal Cancer Medication

Starting treatment for anal cancer involves a series of preparatory steps designed to optimize safety and effectiveness. Before initiating chemotherapy, patients undergo baseline blood tests assessing kidney function, liver enzymes, and blood cell counts, as these organs process and tolerate the drugs. Imaging studies confirm the extent of disease, while consultations with radiation oncology, medical oncology, and sometimes surgery establish a coordinated care plan.

Common side effects of chemoradiation include fatigue, skin irritation in the treatment area, diarrhea, nausea, and temporary myelosuppression—a reduction in blood cell production. Mitomycin C carries a specific risk of hemolytic uremic syndrome, a rare but serious complication affecting the kidneys and blood, making regular monitoring essential. Immunotherapy-related side effects differ considerably from chemotherapy toxicities; they are immune-mediated and can affect virtually any organ system, including the lungs, liver, endocrine glands, and skin.

Patients beginning checkpoint inhibitor therapy are educated about immune-related adverse events (irAEs) and instructed to report new or worsening symptoms promptly. Most irAEs are manageable with corticosteroids if detected early, but delays in reporting can lead to more serious complications. Oncology nurses and pharmacists play a vital role in patient education, ensuring individuals understand their drug schedule, administration route, potential interactions, and when to seek urgent medical attention. Regular follow-up appointments and laboratory monitoring continue throughout and after treatment to assess response and detect late-onset side effects.

Frequently Asked Questions

Are there FDA-approved immunotherapy drugs specifically for anal cancer?

Yes. The FDA has approved nivolumab and pembrolizumab—both PD-1 checkpoint inhibitors—for patients with previously treated, unresectable, or metastatic squamous cell carcinoma of the anal canal. Pembrolizumab also holds a tissue-agnostic approval covering MSI-H or dMMR solid tumors, which can include certain anal cancers. Eligibility is determined through biomarker testing and prior treatment history, and both drugs are administered intravenously in an outpatient oncology setting.

Can anal cancer be treated with oral medications?

Capecitabine, an oral antimetabolite, is used as an alternative to intravenous 5-fluorouracil in some chemoradiation protocols for anal cancer. It is taken twice daily during radiation treatment weeks and converts to active 5-FU within tumor tissue. While not universally standard, it offers a more convenient option for patients who cannot tolerate continuous intravenous infusions. Its use is guided by oncologist preference, patient suitability, and institutional protocols.

How long does anal cancer drug treatment typically last?

Duration varies by treatment type and disease stage. Standard chemoradiation for localized anal cancer spans approximately five to six weeks. Systemic chemotherapy for metastatic disease continues until disease progression or intolerable toxicity, often administered in repeating cycles every two to three weeks. Immunotherapy regimens with nivolumab or pembrolizumab may continue for up to two years in responding patients, as per current FDA-approved labeling and clinical guidelines. Individual plans are tailored by the treating oncologist.